TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rehabilitation in Aortic Stenosis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective surgery with aortic valve replacement for aortic stenosis at the thoracic surgery department at Linköping University hospital, Linköping.~* Geographical residence no further from hospital than permitting visit to Supervised Exercise Training 3 times per week~Exclusion Criteria:~* Any concommitant heart disease~* Other surgical intervention at time of valve replacement~* Age under 18 years~* Symptomatic lung disease~* Any disability or disease hampering participation in exercise training~* Cannot communicate with spoken Swedish

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supervised Exercise Training (Type: EXPERIMENTAL): 12 weeks of 40 min aerobic bicycle ergometer exercise 3 times per week.
- Physical Activity Recommendations (Type: ACTIVE_COMPARATOR): Written and verbal information on minimal level of physical activity recommended.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have a diagnosis of histologically confirmed ovarian, fallopian or primary peritoneal cancer that has progressed or recurred in the abdomen or pelvis after salvage chemotherapy as documented by either:~   1. Radiologic studies or~  2. Rising CA125 levels on two independent measurements. If the patient's CA125 has fallen into a normal range, CA125 relapse will be defined as double the nadir CA125. However, if the patients CA125 nadir had fallen to less than 10, then the measurements documenting recurrence or progression must be greater than 20.~2. There is no limit on prior courses of chemotherapy.~3. Patients must have unidimensional measurable disease or elevated CA125~4. Age greater than 18 years.~5. ECOG performance status less tha 2 (Karnofsky 60%).~6. Life expectancy of greater than 12 weeks.~7. Patients must have adequate organ and marrow function~8. Ability to understand and the willingness to sign a written informed consent document. All patients must be informed of the investigational nature of this study and must sign an informed consent in accordance with institutional and federal guidelines.~9. Timing guideline for pre-study labs and measurements:~All pre-study labs required for determination of eligibility are to be completed within 28 days of treatment Day 1.~X-rays and/or scans used for tumor measurement to determine disease status are to be completed within 28 days of treatment Day 1.~Women of all races and ethnic groups are eligible for this trial.~Exclusion Criteria:~1. Patients with known immunosuppressive diseases are excluded from this trial due to the known immunosuppressive nature of Alemtuzumab therapy.~2. Patients may not be receiving any other agents (investigational or otherwise) with therapeutic intent.~3. Patients with prior malignancy, except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease free for 2 years.~4. Patients with a history of allergic reactions to Alemtuzumab or other humanized immunotherapeutics.~5. Patients with unresolved bacterial, fungal, or viral infections requiring active treatment. Patients may be registered two weeks after the conclusion of antibiotic or anti-viral therapy.~6. Patients with history of active CMV disease as Alemtuzumab therapy has been associated with CMV reactivation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- one (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Satiety in the Effect of Portion Size on Intake

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Be willing and able to travel to Penn State University Park campus weekly for meals~* Be a man or woman 18 - 60 years old~* Regularly eat 3 meals/day~* Be willing to avoid alcohol the day before and during test days~* Have a body mass index between 18.0 and 35.0 kg/m-squared~* Be willing to refrain from eating after 10 pm the evening before test sessions~Exclusion Criteria:~* A smoker~* An athlete in training~* Pregnant or breastfeeding at the time of screening~* Have taken prescription or non-prescription drugs that may affect appetite or food intake within the last 3 months~* Dislike or be unable to eat the test foods (because of allergies, intolerance, or dietary restrictions)~* Currently dieting to gain or lose weight~* Have a health condition that affects appetite~* Have participated in a similar study in our lab in the past year

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 100% Portion Size (Type: EXPERIMENTAL): Test meal consists of baseline (100%) portion size of meal.
- 125% Portion Size (Type: EXPERIMENTAL): Test meal consists of food portion size that is 125% the size of baseline portion.
- 150% Portion Size (Type: EXPERIMENTAL): Test meal consists of food portion size that is 150% the size of baseline portion.
- 175% Portion Size (Type: EXPERIMENTAL): Test meal consists of food portion size that is 175% the size of baseline portion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient being treated at Cincinnati Children's Hospital requiring an allogeneic HSCT who lacks an HLA-genotypically matched related donor. Genotypically matched related donors are allowed when there is a clinical desire to avoid the use of GVHD prophylaxis medications.~Exclusion Criteria:~* Prior allogeneic transplant with active acute or chronic GVHD, or life-threatening infection. Patients with a prior history of allogenic transplant without active GVHD or life-threatening infection can be considered.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TCRαβ+/CD19+ depleted HSCT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18 years of age.~2. Gross total resection (as verified by the lack of any enhancement in the resection cavity on post-operative MRI) of single brain metastasis confirmed by histology. Patients with up to 4 metastases are eligible if the largest mass is amenable to surgical resection and all non-resected masses are amenable to SRS.~3. Patient must be Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) Class 1 or 2.~4. Life expectancy of at least 3 months.~Exclusion Criteria:~1. Radiographic or cytologic evidence of leptomeningeal disease.~2. Patient with incomplete or partial resection.~3. Primary lesion with radiosensitive histology (i.e., small cell carcinoma, germ-cell tumors, lymphoma, leukemia, and multiple myeloma).~4. Patients with a resection cavity \> 4 cm in maximal extent in any plane on contrasted MRI scan.~5. Lesion located in anatomic regions which are not amenable to SRS including the brain stem and optic apparatus.~6. Pregnant or need to breast feed during the study period.~7. Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness.~8. Brain surgery other than for resection of metastasis.~9. Previous brain radiotherapy.~10. Contraindication to SRS, WBRT, or MRI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Post-operative SRS (Type: ACTIVE_COMPARATOR): All patients will undergo SRS with the planned target volume (PTV) defined as the resection cavity plus a 3-mm margin after surgical resection of a single brain metastasis. Dose will be prescribed to the maximum isodose line completely encompassing the PTV using the guidelines established in RTOG 9005. All patients will be evaluated for neurocognitive function via Mini-Mental State Examination (MMSE), Quality of Life (QOL) via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cabozantinib in Advanced Salivary Gland Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Disease specific~* locally advanced, recurrent, and/or metastatic SGC (excluding sarcomas and mesenchymal tumors)~* c-MET positive disease~* Measurable disease per RECIST version 1.1 Cohort-specific criteria~* SDC cohort: direct inclusion (no objective tumor growth prior to inclusion needed)~* ACC cohort: inclusion after objective growth in the last three months or complaints due to the disease~* Other SGC's: inclusion after objective growth in the last three months or complaints due to the disease General conditions~* Age ≥18 years~* Eastern Cooperative Oncology Group performance status of 0 or 1.~* Normal number of neutrophils and thrombocytes~* Liver function: ALT and AST \< 2.5 x upper limit of normal (ULN), total bilirubin ≤ 1.5 x ULN (except for Gilbert's syndrome), serum albumin ≥28 g/L~* Renal function: creatinine \< 1.5 x ULN or calculated creatinine clearance ≥ 40 ml/min, Urine protein/creatinine ratio ≤113.1 mg/mmol (≤1 mg/mg) or 24-hour urine protein \<1 g~* Hemoglobin A1c (HbA1c) ≤ 8% or a fasting serum glucose ≤ 9 mmol/l~Exclusion Criteria:~General conditions~* A known allergy for cabozantinib or its components~* Long QT-syndrome~* Pregnancy or lactation~* Patients (M/F) with reproductive potential not implementing adequate contraceptives measures~* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before inclusion~* Major surgery within 3 months before randomization. Complete wound healing from major surgery must have occurred 1 month before inclusion and from minor surgery at least 10 days before inclusion~* Uncontrolled illness including, but not limited to cardiovascular disorders including symptomatic congestive heart failure, unstable angina pectoris, or serious cardiac arrhythmias, uncontrolled hypertension defined as sustained systolic BP \> 150 mm Hg, or diastolic BP \> 100 mm Hg, stroke (including TIA), myocardial infarction, or other ischemic event within 6 months before inclusion, serious active infections Concomitant treatments~* Concomitant (or within 4 weeks before inclusion) administration of any other experimental drug under investigation.~* Concurrent treatment with any other anti-cancer therapy.~* Concomitant anticoagulation. Low dose aspirin for cardioprotection and low dose LMWH are permitted.~* Radiation therapy within the last 4 weeks before inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cabozantinib (Type: EXPERIMENTAL): cabozantinib 60 mg tablets OD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: STATIN-VAP STATIN-VAP - STATINs and Ventilator-Associated Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Duration of mechanical ventilation \> 48 h~* First episode of suspicion of VAP with a Clinical Pulmonary Infection Score modified ≥ 5~* BAL, plugged telescopic catheter and/or tracheal aspirates quantitative cultures performed prior administration of antibiotics~* Informed consent~Exclusion Criteria:~* Statin treatment received under mechanical ventilation~* Age less than 18 years~* Pregnancy~* Unable to receive or unlikely to absorb enteral study drug~* Patient, surrogate, or physician not committed to full support ).~* Moribund patient with a SAPS II score \> 75~* Simvastatin specific exclusions Allergy or intolerance to statins Physician insistence for the use or avoidance of statins during the current hospitalization CK , ALT or AST \> 5 times the upper limit of normal Receiving cyclosporine, gemfibrozil, lopinavir, ritonavir itraconazole, kétoconazole, érythromycine, clarithromycine, télithromycine, néfazodone, verapamil, diltiazem~* Severe chronic liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PLACEBO (Type: PLACEBO_COMPARATOR): Half of the patients will be randomized to the placebo
- Simvastatin (Type: ACTIVE_COMPARATOR): Half of the subjects will receive the active drug, Simvastatin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine and Refractory Painful Care in a Palliative Unit

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of ≥18 years old, hospitalized in palliative care units~* Conscious or presenting altered/disturbed consciousness but for whom the Rudkin score is ≤ 4 (eyes closed, response to light tactical stimulation)~* For whom a palliative care is acted~* No matter the progression and prognostic status~* After the information is given to the patient (with the notification form given) and the written consent form is retrieved and when the state of cognition and vigilance allows it. In case of cognitive and consciousness disturbance, after informing and retrieving the written consent form from the patient's trusted person, or a relative by default, for patients under guardianship after being informed and giving a consent form written by the legal representative.~* Evened out on an analgesia level, without care~* Who has not received ketamine for 60 days before inclusion no matter the indications~* For whom bedsore, ulcer or vascular injuries have appeared and continue to be painful despite the administration of opioid bolus with the painful evaluation regarding the visual analogic scale (EVA) ≥ 5/10, or regarding the evaluation of the Algoplus pain behavior scale ≥ 2, or for whom the opioid treatment cannot be administered due to the presence of adverse side effects (drowsiness, confusion, nausea, vomiting, respiratory depression...)~* And for whom caring under Entonox (a medical analgesic gas which is a mix of nitrous oxide and oxygen) is inefficient or not compatible.~* Lack of easy venous access~Exclusion Criteria:~* Contraindication of Ketamine in case of anesthesia (AMM) : allergy, porphyria~* Late stage heart failure~* Intracranial hypertension~* Acute heart attack phase~* Unstable psychosis~* Presence of agitation~* Pregnant woman~* Patient with no affiliation to a social security system~* Contraindication of Midazolam: known hypersensitivity to benzodiazepines or any other know excipient of the product, acute respiratory depression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- communicating and none-communicating patients (Type: EXPERIMENTAL): 20 communicating patients (evaluated with the visual analogue pain scale (VAS)) and 20 none-communicating patients or patients presenting cognitive disturbance or vigilance (evaluated with the Algoplus scale)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A STEP for Patients Prior to Undergoing TAVR: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All adult patients scheduled to undergo first-time elective TAVR~Exclusion Criteria:~* Vulnerable populations including prisoners, pregnant females and patients less than 18 years age.~* Patients with history of unstable angina, myocardial infarction, or decompensated heart failure in the week prior to screening~* Patients with physical limitations (i.e. debilitating stroke, amputation, unable to complete initial screening frailty profile)~* Patients with advanced dementia or cognitive deficits (i.e. unable to follow instructions of initial screening frailty profile)~* Exercise-induced arrhythmias

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supervised TAVR Exercise Program (STEP) (Type: EXPERIMENTAL): Subjects in the experimental arm will participate in an individualized 4-week STEP prior to undergoing TAVR. All subjects will undergo serial frailty assessments by a blinded research assistant at baseline, pre-TAVR, and 30-days post-TAVR.
- Standard of Care (Type: NO_INTERVENTION): Subjects in the no intervention arm will proceed with their TAVR after a minimum 4 weeks without an exercise intervention. All subjects will undergo serial frailty assessments by a blinded research assistant at baseline, pre-TAVR, and 30-days post-TAVR.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of the ASI-SR Form in a Population of Chronic Non-cancer Pain Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic non-cancer related pain~* ongoing treatment in the clinic~Exclusion Criteria:~* severe cognitive impairment~* illiterate in Swedish~* inability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Chronic pain (Type: None): Patients with chronic non-cancer pain referred to secondary and tertiary care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Tamsulosin to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* ≥ 35 years (Males \& Females)~* Cervical Laminectomy~* Cervical Posterior Fusion~* Cervical Anterior/Posterior Fusion~* Lumbar Laminectomy~* Lumbar Posterolateral Fusion~* Lumbar Interbody Fusion~Exclusion Criteria~* \< 35 years~* Cervical Anterior Discectomy and Fusion~* Cervical Anterior Corpectomy~* Cervical Posterior Discectomy~* Cervical Foraminotomy~* Lumbar Discectomy (METRx or Open)~* Lumbar Foraminotomy~* Lumbar Anterior Fusion~* Myelopathy with bladder dysfunction~* Patients currently taking an alpha-antagonist~* Patients with history of allergy or sensitivity to tamsulosin or other alpha-antagonist (alfuzosin, doxazosin, prazosin, terazosin, tamsulosin, and phenoxybenzamine)~* History of prostatectomy or urologic surgery involving the bladder or urethra~* Severe liver disease or end-stage renal disease~* Patients taking strong inhibitors of CYP3A4 (ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir/ritonavir, lopinavir/ritonavir, and conivaptan)~* Patients with a mental disability~* Prisoners

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tamsulosin (Type: EXPERIMENTAL): Participants randomized to this arm will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to this arm will receive a daily placebo capsule matching the active study drug from 5 days prior to the operation until hospital discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues